Health ConditionsDiabetesType 2 Diabetes

Everything You Need to Know About Tirzepatide (Mounjaro) for Type 2 Diabetes

Everything You Need to Know About Tirzepatide (Mounjaro) for Type 2 Diabetes
Eli Lilly; Everyday Health
By
Updated on October 30, 2026
by
Add us on Google

Next up video playing in 10 seconds

What’s the Difference Between Ozempic and Mounjaro?

Leading endocrinologist Caroline Messer, MD, offers her advice on the newest weight loss medications.
Managing type 2 diabetes often involves finding a medication that does more than lower blood sugar. Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for weight management and certain cases of obstructive sleep apnea — activates two hormone receptors to help regulate blood sugar and can support weight loss.

On August 28, 2026, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) had also approved Mounjaro to reduce the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with type 2 diabetes who are at high risk for these events.

If you’re considering tirzepatide, here’s a guide to how the medication works, its potential benefits and side effects, and how to start the conversation with your doctor.

What Is Tirzepatide and How Do GLP-1 and GIP Receptor Agonists Work?

Tirzepatide (Mounjaro and Zepbound) is the first FDA-approved drug that is part of a drug class called glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.

Tirzepatide is administered as a once-weekly injection under the skin of your abdomen or thigh, or another person can inject it in the back of your upper arm. It’s available in pen and vial presentations, not as an FDA-approved pill. Adult doses range from 2.5 milligrams (mg) to 15 mg; the maximum weekly dose for children ages 10 years and older is 10 mg.

“Mounjaro has to be titrated when it is started, meaning a gradual dose increase happens over many months, to allow the body to adjust to the medication and lower the risk of side effects,” says Florencia Halperin, MD, a Boston-based endocrinologist who is the chief medical officer of the weight loss clinic Form Health.

Infographic covering key facts on Tirzepatide Mounjaro, including dual action, weight loss, heart health, and dosing.
Everyday Health, Adobe Stock.

The Mechanism Behind GLP-1 and GIP Receptor Agonists

Tirzepatide mimics the actions of two incretin hormones: GLP-1 and GIP. It increases insulin secretion when blood sugar is elevated, slows stomach emptying, and reduces food intake.

The insulin then helps your body use or store glucose (sugar) in a way that the body can’t on its own due to type 2 diabetes. With type 2 diabetes, the body can’t handle insulin as efficiently as it should, and you can develop high blood sugar, or hyperglycemia.

The drug affects multiple organs, mimicking and stimulating both the GIP and GLP-1 receptors in our bodies, Dr. Halperin says.

“These receptors are found in the pancreas, where stimulation leads to increased insulin secretion. They are also found in the appetite centers of the brain. GLP-1 also slows down stomach emptying, so people feel fuller sooner and longer. And GIP is known to act on our fat cells in a variety of ways,” Halperin says.

What’s the Difference Between Tirzepatide and Semaglutide?

The drug may sound similar to another type 2 diabetes and weight loss drug, semaglutide, which is a GLP-1 receptor agonist. Similar to tirzepatide, semaglutide — sold as the type 2 diabetes drug Ozempic and the obesity drug Wegovy — mimics the hormone GLP-1 and triggers the body to make more insulin when blood sugar levels rise after eating.

Tirzepatide is different from semaglutide because it also mimics the GIP hormone.

What Is Tirzepatide Approved to Treat?

The FDA initially approved Mounjaro on May 13, 2022, to improve blood sugar control in adults with type 2 diabetes alongside diet and exercise. Its indication now includes children ages 10 and older.

Lilly announced the additional cardiovascular risk indication for high-risk adults with type 2 diabetes in August 2026.

The FDA approved Zepbound for chronic weight management on November 8, 2023, in adults with obesity or adults who are overweight and have at least one weight-related condition. It’s used with a reduced-calorie diet and increased physical activity.

On December 20, 2024, the FDA also approved Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro and Zepbound contain the same active ingredient but have different approved uses.

Tirzepatide is not FDA-approved to treat type 1 diabetes. However, a small randomized trial published in January 2026 found greater weight loss with tirzepatide than placebo over 12 weeks in adults with type 1 diabetes and obesity.

 A newer observational study, published online in July 2026, also found improvements in weight, blood sugar, and insulin requirements over 12 months.

 These findings are promising, but larger randomized trials are needed to establish long-term effectiveness and safety for this use.

Only your healthcare team can determine if this medication is a good fit for you, so be sure to consult them to discuss what’s right for your health and wellness goals.

Which Type 2 Diabetes Health Complications Can GLP-1 and GIP Receptor Agonists Help Treat?

Tirzepatide is FDA-approved for treating hyperglycemia , a symptom of type 2 diabetes.

Mounjaro improves blood sugar control in type 2 diabetes. The cardiovascular indication announced in August 2026 applies to high-risk adults with type 2 diabetes, not everyone taking tirzepatide.

Under the Zepbound brand, tirzepatide is approved for weight management in eligible adults and for moderate to severe obstructive sleep apnea in adults with obesity.

Which Brand-Name GLP-1 and GIP Receptor Agonists Have Been Approved by the FDA?

Mounjaro and Zepbound contain tirzepatide, a dual GIP and GLP-1 receptor agonist. Mounjaro is approved for type 2 diabetes and cardiovascular risk reduction in eligible adults; Zepbound is approved for weight management and obstructive sleep apnea in eligible adults.


Other medications used for type 2 diabetes target GLP-1 receptors alone. Examples include dulaglutide (Trulicity), semaglutide (Ozempic), and liraglutide (Victoza).

What Are the Potential Benefits of GLP-1 and GIP Receptor Agonists?

Research has shown that tirzepatide can improve blood sugar control and support weight loss. Its benefits now also include an approved use for cardiovascular risk reduction in high-risk adults with type 2 diabetes.

Better Blood Sugar Management in Type 2 Diabetes

Tirzepatide has shown significant effectiveness in lowering blood sugar in adults with type 2 diabetes. In the SURPASS-2 trial, the 15-mg dose reduced A1C by an average of 2.3 percentage points after 40 weeks, compared with 1.9 percentage points with 1 mg of semaglutide. These results describe the doses studied, not every semaglutide dose or formulation.

A1C is a two- to three-month average of blood sugar levels, according to the Centers for Disease Control and Prevention.

Other SURPASS trials found greater A1C reductions with tirzepatide than with the long-acting insulins degludec and glargine. Tirzepatide can still cause low blood sugar, particularly when taken with insulin or a sulfonylurea.

Weight Loss

Tirzepatide appears to be exceptionally effective for weight loss in people with and without type 2 diabetes, according to two clinical trials that tested its effectiveness for that use.

In the SURMOUNT-1 trial, which enrolled adults without diabetes, average weight loss after 72 weeks reached 20.9 percent with 15 mg of tirzepatide, compared with 3.1 percent with placebo. Participants also followed a reduced-calorie diet and increased physical activity.

In SURMOUNT-2, which studied adults with type 2 diabetes and a body mass index (BMI) of at least 27, average weight reductions after 72 weeks were 12.8 percent with 10 mg of tirzepatide and 14.7 percent with 15 mg, compared with 3.2 percent with placebo. About 79 to 83 percent of participants taking tirzepatide lost at least 5 percent of their body weight, compared with 32 percent of those taking placebo.

Lower Risk of Heart Attack and Stroke

On August 28, 2026, Lilly announced that the FDA had approved Mounjaro to reduce the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with type 2 diabetes who are at high risk for these events.

The approval was based on the SURPASS-CVOT study, which compared tirzepatide with dulaglutide (Trulicity), a medication with established cardiovascular benefits. More than 13,000 adults with type 2 diabetes and established cardiovascular disease participated.

Heart attack, stroke, or cardiovascular death occurred in 12.2 percent of the tirzepatide group and 13.1 percent of the dulaglutide group over a median follow-up of about four years. Tirzepatide met the trial’s criteria for being no worse than dulaglutide, but it wasn’t shown to be statistically superior. That distinction is important: The study supports cardiovascular benefits without establishing that Mounjaro prevents these events better than Trulicity.

Improved Blood Pressure

Beneficial effects on systolic blood pressure (a measure of how much pressure is exerted against your artery walls when your heart is beating) have been found across the series of SURPASS trials that studied tirzepatide in people with type 2 diabetes. Systolic pressure dropped by between 4.2 mmHg and 12.6 mmHg after 40 to 42 weeks in participants receiving tirzepatide, mostly attributed to weight loss.

Louis Aronne, MD, an endocrinologist, director of the Comprehensive Weight Control Center at Weill Cornell Medicine in New York City, and coauthor of the New England Journal of Medicine study on tirzepatide for obesity treatment, describes the Mounjaro results as “spectacular,” and for those in the highest weight categories, comparable with bariatric surgery results. “It's really quite a remarkable finding.”

Have GLP-1 and GIP Receptor Agonists Been Studied in BIPOC?

The effects of tirzepatide for type 2 diabetes control have been studied in detail in some members of Black, Indigenous, and People of Color (BIPOC) communities. For example, it shows promise for people in East Asian and Hispanic/Latino populations, Dr. Aronne says.

Results of the SURPASS-J trials in Japanese populations and analyses of data from Hispanic/Latino SURPASS-2 trial participants are examples. “Those are two areas we can address, and the answer is, it works just as well,” Aronne says.

Noting that Asian people tend to have lower BMIs — as well as lower BMI thresholds for obesity, as reported by the World Health Organization — he adds that tirzepatide “seems to be as effective and produced equivalent reductions in glucose in the SURPASS trials. But more work needs to be done to ensure that these outcomes are just as good in other ethnic groups.”

What Are the Possible Side Effects of Tirzepatide?

The most common side effects of tirzepatide are gastrointestinal. These side effects are typically mild and often decrease over time as your body adjusts to the medication. They include:

  • Nausea and vomiting
  • Constipation
  • Diarrhea
  • Decreased appetite
  • Indigestion
  • Stomach pain

Nausea, vomiting, and diarrhea often occur during dose increases and tend to decrease over time. Severe gastrointestinal reactions can also occur.

Tirzepatide carries a boxed warning for the potential risk of thyroid C-cell tumors. These tumors occurred in rats; whether tirzepatide causes them, including medullary thyroid carcinoma, in humans is unknown.

“Mounjaro shouldn't be used in patients with, or who have a family history of, certain types of thyroid cancer such as medullary thyroid carcinoma, or in patients with multiple endocrine neoplasia type 2 (a genetic disorder of the endocrine glands),” says Florence Comite, MD, an endocrinologist who is the founder of the Comite Center for Precision Medicine and Healthy Longevity in New York City.

Other important warnings include pancreatitis, serious allergic reactions, gallbladder disease, dehydration-related kidney injury, and possible worsening of diabetic retinopathy in people with a history of the condition. Mounjaro isn’t recommended for people with severe gastroparesis, a condition that slows stomach emptying.

The prescribing information lists reports of ileus, intestinal obstruction, and severe constipation after approval. These voluntary reports cannot reliably establish how often the problems occur or whether tirzepatide caused them.

People taking Mounjaro should let their healthcare team know before undergoing procedures that require general anesthesia or deep sedation, because delayed stomach emptying may increase the risk of stomach contents entering the lungs.

Do GLP-1 and GIP Receptor Agonists Interact Negatively With Other Drugs?

According to the FDA-listed drug label information for Mounjaro, it has the potential to affect the absorption of other medications because it delays gastric emptying. Be sure to check with your healthcare provider before taking Mounjaro and describe all the medications you are taking. This will help you avoid any possible medication interactions.

People using oral hormonal contraceptives should switch to a non-oral contraceptive or add a barrier method for four weeks after starting Mounjaro and for four weeks after each dose increase. Taking Mounjaro with insulin or a sulfonylurea can increase the risk of low blood sugar, so a prescriber may need to adjust those medications.

Are There Any Diet and Lifestyle Changes You Should Make With GLP-1 and GIP Receptor Agonists?

In short, yes. Put differently, tirzepatide doesn’t give you license to ditch a balanced diet and healthy lifestyle. In fact, tirzepatide is specifically approved to be used in conjunction with a balanced diet and regular exercise to manage type 2 diabetes.

“These medications are less likely to work without changes to underlying habits and lifestyle,” says Jessica Cutler, MD, a bariatric surgeon at Mercy Medical Center in Baltimore. “I believe that without those changes, weight regain is very likely if the medication is stopped. That said, some of the effects of the medication, like earlier satiety and decreased cravings, may make it easier to commit to some of these other [lifestyle] changes. So far, that is what I have observed in most of my patients who are taking Mounjaro.”

Participants in the initial trial of tirzepatide for weight loss (SURMOUNT-1) ate a diet with a deficit of 500 calories per day, and did at least 150 minutes of physical activity each week, so research also suggests the drug — as effective as it may be for some people — is not a silver bullet for weight loss.

FAQ

How does tirzepatide work?

It mimics the actions of two hormones, GLP-1 and GIP, which work together to stimulate insulin secretion and slow stomach emptying after a meal, signal to the brain that you feel full, and regulate fat cells. All this helps regulate blood sugar levels and cause weight loss.

Yes. In SURMOUNT-2, adults with type 2 diabetes lost an average of 12.8 percent of their body weight with tirzepatide 10 mg and 14.7 percent with 15 mg after 72 weeks, compared with 3.2 percent with placebo.

Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain. Tirzepatide also carries warnings for serious risks, including pancreatitis and a potential risk of thyroid C-cell tumors.

It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. It caused these tumors in rats, which is why it carries a boxed warning. Mounjaro should not be used by people with a personal or family history of medullary thyroid carcinoma or by people with multiple endocrine neoplasia syndrome type 2.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Mounjaro (Tirzepatide) U.S. Prescribing Information. Lilly. August 2026.
  2. Zepbound (Tirzepatide) U.S. Prescribing Information. Lilly. August 2026.
  3. FDA Approves Lilly's Mounjaro (Tirzepatide) to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes. Lilly. August 28, 2026.
  4. Hyperglycemia in Diabetes: Symptoms and Causes. Mayo Clinic. September 2, 2026.
  5. Diabetes Drugs and Weight Loss. Mayo Clinic. November 14, 2024.
  6. Drug Trials Snapshots: Mounjaro. U.S. Food and Drug Administration. June 13, 2023.
  7. FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration. November 8, 2023.
  8. FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration. December 20, 2024.
  9. Snaith JR et al. Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. Diabetes Care. January 1, 2026.
  10. Berry SA et al. Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers. Diabetes, Obesity and Metabolism. October 2026.
  11. A1C Test for Diabetes and Prediabetes. Centers for Disease Control and Prevention. May 15, 2024.
  12. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. Lancet. August 19, 2023.
  13. Nicholls SJ et al. Cardiovascular Outcomes With Tirzepatide Versus Dulaglutide in Type 2 Diabetes. The New England Journal of Medicine. December 18, 2025.
  14. Lingvay I et al. Systolic Blood Pressure Reduction With Tirzepatide in Patients With Type 2 Diabetes: Insights From SURPASS Clinical Program. Cardiovascular Diabetology. March 24, 2023.
  15. Inagaki N et al. Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes (SURPASS J-Mono): A Double-Blind, Multicentre, Randomised, Phase 3 Trial. The Lancet Diabetes & Endocrinology. September 2022.
  16. Benneyworth BD et al. OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2. Journal of the Endocrine Society. November 1, 2022.
  17. Tirzepatide (Subcutaneous Route). Mayo Clinic. October 1, 2026.
  18. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. June 4, 2022.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network
Anna-L-Goldman-bio

Anna L. Goldman, MD

Medical Reviewer
Castle Connolly Top Doctor

Anna L. Goldman, MD, is a board-certified endocrinologist. She teaches first year medical students at Harvard Medical School and practices general endocrinology in Boston.

Dr. Goldm...

See full bio

Sheryl Huggins Salomon

Author

Sheryl Huggins Salomon has spent her career equipping people with information to help improve their well-being and prospects in life. She is a veteran journalist and editor who has...

See full bio
See Our Editorial PolicyMeet Our Health Expert Network